Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
Erik S. Linklater(Van Andel Institute), Carrie R. Graveel(Van Andel Institute)
Cited by 80
Related Papers
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
|Clinical Cancer Research|2017|147
Rab40/Cullin5 complex regulates EPLIN and actin cytoskeleton dynamics during cell migration and invasion
|bioRxiv (Cold Spring Harbor Laboratory)|2021|2